MCM2 and pancreatic adenocarcinoma: For pancreatic adenocarcinoma diagnosis, the 1-specificity (proportion of false positive) and sensitivity (proportion of true positive) of JUB was 51.6% and 86.5%, respectively; the 1- specificity and sensitivity and of ERLIN1 was 80.6% and 57.7%, respectively; the 1- specificity and sensitivity and of FAM110B was 48.4% and 88.5%, respectively; the 1- specificity and sensitivity and of MCM2 was 80.6% and 57.7%, respectively; the 1- specificity and sensitivity and of BCL2L1 was 51.6% and 85.7%, respectively.